Overview

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Status:
Completed

Trial end date:
2015-09-15

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

MedImmune LLC